Sequence-specific DNA binding by p53: identification of target sites and lack of binding to p53 - MDM2 complexes
- PMID: 8334996
- PMCID: PMC413530
- DOI: 10.1002/j.1460-2075.1993.tb05941.x
Sequence-specific DNA binding by p53: identification of target sites and lack of binding to p53 - MDM2 complexes
Abstract
An immune selection procedure was employed in order to isolate p53 binding sites from mouse genomic DNA. Two DNA clones capable of tight specific interaction with wild type p53 were subjected to further characterization. In both cases, the p53 binding regions displayed a high degree of sequence homology with the consensus binding site defined for human genomic DNA. One of the clones was found to be derived from the LTR of a retrovirus-like element (a member of the GLN family). The region encompassing the GLN LTR p53 binding site could confer p53 responsiveness upon a heterologous promoter. Furthermore, the expression of the endogenous, chromosomally integrated GLN elements was significantly induced upon activation of wild type p53 in cells harboring a temperature sensitive p53 mutant. Finally, it was demonstrated that p53 - MDM2 complexes fail to bind tightly to such a p53 binding site. This may contribute to the inhibition by MDM2 of p53-mediated transcriptional activation.
Similar articles
-
Targets for transcriptional activation by wild-type p53: endogenous retroviral LTR, immunoglobulin-like promoter, and an internal promoter of the mdm2 gene.Cold Spring Harb Symp Quant Biol. 1994;59:225-35. doi: 10.1101/sqb.1994.059.01.027. Cold Spring Harb Symp Quant Biol. 1994. PMID: 7587074 No abstract available.
-
p53 binds to a constitutively nucleosome free region of the mdm2 gene.Oncogene. 1998 Mar 5;16(9):1171-81. doi: 10.1038/sj.onc.1201631. Oncogene. 1998. PMID: 9528859
-
The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.Cell. 1992 Jun 26;69(7):1237-45. doi: 10.1016/0092-8674(92)90644-r. Cell. 1992. PMID: 1535557
-
The MDM2-p53 interaction.Mol Cancer Res. 2003 Dec;1(14):1001-8. Mol Cancer Res. 2003. PMID: 14707283 Review.
-
Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface.Mol Cancer Res. 2004 Jan;2(1):20-8. Mol Cancer Res. 2004. PMID: 14757842 Review.
Cited by
-
Tight DNA binding and oligomerization are dispensable for the ability of p53 to transactivate target genes and suppress transformation.EMBO J. 1993 Jul;12(7):2789-97. doi: 10.1002/j.1460-2075.1993.tb05940.x. EMBO J. 1993. PMID: 8334995 Free PMC article.
-
p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs.J Exp Med. 1998 Dec 7;188(11):2033-45. doi: 10.1084/jem.188.11.2033. J Exp Med. 1998. PMID: 9841917 Free PMC article.
-
Mechanisms of TP53 Pathway Inactivation in Embryonic and Somatic Cells-Relevance for Understanding (Germ Cell) Tumorigenesis.Int J Mol Sci. 2021 May 20;22(10):5377. doi: 10.3390/ijms22105377. Int J Mol Sci. 2021. PMID: 34065345 Free PMC article. Review.
-
MdmX is required for p53 interaction with and full induction of the Mdm2 promoter after cellular stress.Mol Cell Biol. 2012 Apr;32(7):1214-25. doi: 10.1128/MCB.06150-11. Epub 2012 Jan 30. Mol Cell Biol. 2012. PMID: 22290440 Free PMC article.
-
Low Grade Amplification of MDM2 Gene in a Subset of Human Breast Cancers without p53 Alterations.Breast Cancer. 1994 Dec 30;1(2):95-102. doi: 10.1007/BF02967038. Breast Cancer. 1994. PMID: 11091516
References
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous